BC
ABBV icon

Burleson & Co’s AbbVie ABBV Stock Holding History

Burleson & Co’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$6.08M Buy
37,600
+5,014
+15% +$769K 1.52% 19
2022
Q3 		$4.37M Buy
32,586
+1,594
+5% +$229K 0.94% 28
2022
Q2 		$4.75M Sell
30,992
-196
-0.6% -$29.9K 1.03% 28
2022
Q1 		$5.06M Sell
31,188
-1,164
-4% -$169K 0.81% 33
2021
Q4 		$4.38M Sell
32,352
-759
-2% -$89.7K 0.64% 33
2021
Q3 		$3.57M Sell
33,111
-1,249
-4% -$143K 0.53% 37
2021
Q2 		$3.87M Buy
34,360
+218
+0.6% +$24.6K 0.56% 41
2021
Q1 		$3.69M Sell
34,142
-3,566
-9% -$381K 0.6% 30
2020
Q4 		$4.04M Sell
37,708
-154
-0.4% -$14.8K 0.7% 29
2020
Q3 		$3.52M Sell
37,862
-80,695
-68% -$7.6M 0.67% 33
2020
Q2 		$11M Buy
118,557
+21,452
+22% +$1.89M 2.4% 11
2020
Q1 		$8.15M Buy
97,105
+52,988
+120% +$4.51M 2.12% 11
2019
Q4 		$3.85M Buy
44,117
+37
+0.1% +$3.07K 1.08% 21
2019
Q3 		$3.43M Buy
44,080
+3,607
+9% +$247K 1.2% 22
2019
Q2 		$2.66M Buy
40,473
+14,062
+53% +$1.11M 1.12% 24
2019
Q1 		$2.08M Hold
26,411
– – 0.88% 31
2018
Q4 		$2.08M Sell
26,411
-1,923
-7% -$169K 1.07% 24
2018
Q3 		$2.54M Buy
28,334
+10,467
+59% +$993K 1.42% 17
2018
Q2 		$1.66M Buy
17,867
+1,005
+6% +$98.2K 0.96% 34
2018
Q1 		$1.6M Buy
16,862
+8
+0% +$879 1.04% 31
2017
Q4 		$1.63M Buy
+16,854
New +$1.59M 1.05% 25

Other funds holding ABBV

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Burleson & Co's ABBV Position: Q4 2022 in Review

Burleson & Co increased its AbbVie (ABBV) stake by 15% in Q4 2022, buying an estimated $769K and bringing the position to 37,600 shares worth $6.08M. The position accounts for 1.52% of the portfolio, ranked #19.

Burleson & Co first reported a position in ABBV in Q4 2017 and has held it in 21 quarters since. The position peaked at $11M in Q2 2020. 3,168 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.

  • Burleson & Co held 37,600 shares of AbbVie worth $6.08M as of Q4 2022.
  • Burleson & Co bought 5,014 AbbVie shares in Q4 2022, an estimated $769K.
  • AbbVie made up 1.52% of Burleson & Co's portfolio in Q4 2022, its #19 holding.
  • Burleson & Co first reported a position in AbbVie in Q4 2017 and has held it in 21 quarters since.
  • Burleson & Co's AbbVie position peaked at $11M in Q2 2020.
  • 3,168 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.

Based on Burleson & Co's 13F filing for Q4 2022, filed 31 Jan 2023.